
SPAC
Inside the Nanyang Biologics SPAC Deal: Valuation, Risks, Close
Nanyang Biologics is a Singapore-based AI-driven drug discovery and biotech company going public through a merger with RF Acquisition Corp II (NASDAQ: RFAI). The setup offers a high-upside AI biotech story, but shareholders should watch valuation, redemptions, and dilution closely.
Aug 21, 20267 MIN